Pancreatic Cancer Research

ResearcherChiba Cancer CenterActive in the last 2 years

Kentaro Sudo

Verified by OpenAlex author ID (good confidence, 0.85), identity_conf@1As of 7 November 2026

Matched on OpenAlex author ID A5113641425. Sources: OpenAlex.

Their work

Papers
18 (first author 1, last author 1)
Trials
0
Grants
0
Labs led
0
Collaborators
76
Papers, trials and grants by year

2011: 2 papers · 2012: 1 paper · 2013: none · 2014: 2 papers · 2015: none · 2016: 1 paper · 2017: 1 paper · 2018: 1 paper · 2019: 3 papers · 2020: 1 paper · 2021: none · 2022: none · 2023: 3 papers · 2024: 2 papers · 2025: none · 2026: 1 paper

Papers 18

  1. Establishment of simple pancreatic ductal adenocarcinoma identification method: S100P measurement in duodenal fluid obtained during upper gastrointestinal endo… Co-author DOI 10.1016/j.pan.2025.12.020↗
  2. Clinical utility of BRCA and ATM mutation status in circulating tumour DNA for treatment selection in advanced pancreatic cancer. Co-author DOI 10.1038/s41416-024-02834-0↗
  3. A Phase 2 study of nivolumab in combination with modified FOLFIRINOX for metastatic pancreatic cancer. Co-author DOI 10.1038/s44276-023-00028-4↗
  4. Clinical significance of circulating-tumour DNA analysis by metastatic sites in pancreatic cancer. Co-author DOI 10.1038/s41416-023-02189-y↗
  5. Effect of systemic inflammatory response on induction chemotherapy followed by chemoradiotherapy for locally advanced pancreatic cancer: an exploratory subgrou… Co-author DOI 10.1093/jjco/hyad044↗
  6. FOLFIRINOX in Pancreatic Cancer: Risk Factors for Febrile Neutropenia and Severe Neutropenia - Nationwide Study Analysis. Co-author DOI 10.21873/anticanres.16601↗
  7. FOLFIRINOX as second-line chemotherapy for advanced pancreatic cancer: A subset analysis of data from a nationwide multicenter observational study in Japan. Co-author DOI 10.1016/j.pan.2020.07.006↗
  8. Gemcitabine plus nab-paclitaxel for locally advanced or borderline resectable pancreatic cancer. First author DOI 10.1038/s41598-019-52486-x↗
  9. Impact of UGT1A1 genetic polymorphism on toxicity in unresectable pancreatic cancer patients undergoing FOLFIRINOX. Co-author DOI 10.1111/cas.13883↗
  10. A double-blind randomized comparative clinical trial to evaluate the safety and efficacy of dendritic cell vaccine loaded with WT1 peptides (TLP0-001) in combi… Co-author DOI 10.1186/s13063-019-3332-5↗
  11. Nationwide Multicenter Observational Study of FOLFIRINOX Chemotherapy in 399 Patients With Unresectable or Recurrent Pancreatic Cancer in Japan. Co-author DOI 10.1097/mpa.0000000000001049↗
  12. Phase II study of induction gemcitabine and S-1 followed by chemoradiotherapy and systemic chemotherapy using S-1 for locally advanced pancreatic cancer. Co-author DOI 10.1007/s00280-017-3350-5↗
  13. A case of needle tract seeding after EUS-guided FNA in pancreatic cancer, detected by serial positron emission tomography/CT. Last author DOI 10.1016/j.gie.2016.01.060↗
  14. Randomized controlled study of gemcitabine plus S-1 combination chemotherapy versus gemcitabine for unresectable pancreatic cancer. Co-author DOI 10.1007/s00280-013-2368-6↗
  15. S-1 in the treatment of pancreatic cancer. Co-author DOI 10.3748/wjg.v20.i41.15110↗
  16. Usefulness of brush cytology combined with pancreatic juice cytology in the diagnosis of pancreatic cancer: significance of pancreatic juice cytology after bru… Co-author DOI 10.1097/mpa.0b013e31825d60fc↗
  17. Phase II study of S-1 in patients with gemcitabine-resistant advanced pancreatic cancer. Co-author DOI 10.1007/s00280-010-1311-3↗
  18. Phase II study of oral S-1 and concurrent radiotherapy in patients with unresectable locally advanced pancreatic cancer. Co-author DOI 10.1016/j.ijrobp.2010.01.027↗

Closest collaborators

The 25 strongest of 76 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Nobumasa Mizuno · 7 shared papers, 2018–2024 · strength 0.78
  2. Naohiro Okano · 7 shared papers, 2018–2024 · strength 0.78
  3. Makoto Ueno · 5 shared papers, 2019–2024 · strength 0.69
  4. Masato Ozaka · 6 shared papers, 2018–2024 · strength 0.65
  5. Masafumi Ikeda · 4 shared papers, 2023–2024 · strength 0.62
  6. Chigusa Morizane · 3 shared papers, 2023–2024 · strength 0.50
  7. Satoshi Kobayashi · 5 shared papers, 2018–2023 · strength 0.49
  8. Akiko Todaka · 5 shared papers, 2018–2023 · strength 0.49
  9. Taketo Yamaguchi · 7 shared papers, 2011–2019 · strength 0.40
  10. Keiko Kamei · 4 shared papers, 2018–2023 · strength 0.37
  11. Hideyuki Hayashi · 4 shared papers, 2018–2023 · strength 0.37
  12. Noritoshi Kobayashi · 4 shared papers, 2018–2023 · strength 0.37
  13. Masayuki Furukawa · 3 shared papers, 2019–2024 · strength 0.35
  14. Junji Furuse · 2 shared papers, 2023–2024 · strength 0.34
  15. Takuji Okusaka · 2 shared papers, 2023–2024 · strength 0.34
  16. Kazuo Hara · 2 shared papers, 2019–2026 · strength 0.31
  17. Akio Katanuma · 2 shared papers, 2019–2026 · strength 0.31
  18. Masayuki Kitano · 2 shared papers, 2019–2026 · strength 0.31
  19. Nobuhisa Matsuhashi · 2 shared papers, 2023–2024 · strength 0.28
  20. Kumiko Umemoto · 2 shared papers, 2023–2024 · strength 0.28
  21. Koushiro Ohtsubo · 2 shared papers, 2023–2024 · strength 0.28
  22. Yasuyuki Kawamoto · 2 shared papers, 2023–2024 · strength 0.28
  23. Shinji Itoh · 2 shared papers, 2023–2024 · strength 0.28
  24. Emiri Kita · 3 shared papers, 2016–2019 · strength 0.28
  25. Masafumi Nakamura · 1 shared paper, 2026 · strength 0.24

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.